Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT05174910

Investigation of the Benefit of Using an Autologous Platelet-rich Fibrin Matrix (Obsidian ASG®) for Treatment of Anastomosis During Rectal Surgery

Investigation of the Benefit of Using an Autologous Platelet-rich Fibrin Matrix (Obsidian ASG®) for Treatment of Anastomosis During Rectal Surgery - a Single-blind, Randomized, Multicenter Pilot Study

Status
Active Not Recruiting
Phase
N/A
Study type
Interventional
Enrollment
250 (estimated)
Sponsor
Vivostat · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Anastomotic insufficiency remains one of the most significant problems after rectal resection.The complications following anastomotic insufficiency leads to increased morbidity and mortality with subsequent prolongation of hospital stay and higher costs. This study is an investigation of the benefit of using an autologous platelet-rich fibrin matrix (Obsidian ASG®) for treatment of anastomosis during rectal surgery - a single-blind, randomized, multicenter pilot study with enrollment of 2x125 patients The main objective of the study is to investigate on an exploratory basis whether the use of Obsidian ASG® during rectal resection reduces the frequency of postoperative anastomotic insufficiency compared to standard anastomotic technique. The secondary objectives of the study are to investigate on an exploratory basis: * The frequency of anastomotic insufficiency (ISREC Criteria) severity * Staple line bleeding requiring surgical intervention * The duration of postoperative hospitalization are reduced when using Obsidian ASG ® compared with standard anastomotic treatment alone. are reduced when Obsidian ASG ® is added to the standard of anastomotic treatment compared with standard anastomotic treatment alone.

Conditions

Interventions

TypeNameDescription
DEVICEObsidian ASGApplication of an autologous platelet-rich fibrin matrix

Timeline

Start date
2021-12-23
Primary completion
2024-10-31
Completion
2024-12-31
First posted
2022-01-03
Last updated
2024-07-25

Locations

13 sites across 5 countries: Austria, Germany, Italy, Serbia, Spain

Source: ClinicalTrials.gov record NCT05174910. Inclusion in this directory is not an endorsement.